Clinical trial
ZK-Epo Given With Prednisone in Patients With Metastatic Androgen-independent…
NCT00350051 · Bayer, Industry · Completed
Key facts
| NCT number | NCT00350051 |
|---|---|
| Title | ZK-Epo Given With Prednisone in Patients With Metastatic Androgen-independent Prostate Cancer |
| Official title | Phase 2 Study of ZK-Epothilone (ZK-Epo; ZK219477) Plus Prednisone as First-line Chemotherapy in Patients With Metastatic Androgen-independent Prostate Cancer |
| Lead sponsor | Bayer, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Prostate Cancer |
| Intervention type | Drug |
| Interventions | Sagopilone (ZK 219477) + prednisone |
| Enrollment | 53 |
| Start date | Aug 1, 2006 |
| Primary completion | Sep 24, 2008 |
| Completion | Dec 21, 2009 |
| First posted | Jul 10, 2006 |
| Last update posted | Apr 8, 2021 |
| Countries | Argentina, United States |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: